

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/753,008	01/02/2001	Stefan Somlo	96700/658	1280	
7.	590 03/11/2003				
AMSTER, RO	OTHSTEIN & EBEN	EXAMINER			
Attorneys for A 90 Park Avenu	Applicants	SCHNIZER, HOLLY G			
New York, NY	10016		ART UNIT	PAPER NUMBER	
			1653	40	
			DATE MAILED: 03/11/2003	8	

Please find below and/or attached an Office communication concerning this application or proceeding.

Applicant(s) SOMLO ET AL. Office Action Summary **Art Unit** Examiner Holly Schnizer 1653 -- The MAILING DATE f this communication appears on the cover sheet with the correspondence address --**Period for Reply** A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). **Status** Responsive to communication(s) filed on 24 October 2001. 1)🔯 2b) This action is non-final. 2a)□ This action is FINAL. Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. **Disposition of Claims** 4) Claim(s) 1-75 is/are pending in the application. 4a) Of the above claim(s) _____ is/are withdrawn from consideration. 5) Claim(s) _____ is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) ____ is/are objected to. 8) Claim(s) 1-75 are subject to restriction and/or election requirement. **Application Papers** 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on ____ is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). 11) The proposed drawing correction filed on ____ is: a) approved b) disapproved by the Examiner.

	• •		 	 		_

riority under 35 U.S.C. §§ 119 and 120
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:
1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).

If approved, corrected drawings are required in reply to this Office action.

12) The oath or declaration is objected to by the Examiner.

Attachment(s)

1) Notice of References Cited (PTO-892)	4) Interview Summary (PTO-413) Paper No(s).
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	5) Notice of Informal Patent Application (PTO-152)
3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	6) Other: .

a) The translation of the foreign language provisional application has been received. 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Art Unit: 1653

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-6 and 16-31, drawn to PKD2 nucleic acid molecules, vectors, host cells, and methods of making the PKD2 protein, classified in class 435, subclass 69.1.
- II. Claims 7-15, drawn to nucleic acid probes, classified in class 536, subclass 24.3.
- III. Claims 32-35, drawn to PKD2 proteins, classified in class 530, subclass 350.
- IV. Claims 36-46, drawn to antibodies that specifically recognize PKD2 proteins, classified in class 424, subclass 130.1.
- V. Claims 47-51 and 55-56, drawn to a method of diagnosing ADPKD by detecting mutant PKD2 polynucleotides, classified in class 435, subclass
 6.
- VI. Claims 52-54, drawn to a method of diagnosing ADPKD by detecting mutant PKD2 proteins, classified in class 435, subclass 7.1.
- VII. Claims 57-72, drawn to a method of treatment by gene therapy and products used in the method, classified in class 514, subclass 44.
- VIII. Claims 73-75, drawn to a transgenic animal, classified in class 800, subclass 21.

The inventions are distinct, each from the other because of the following reasons:

Art Unit: 1653

Inventions I-IV and VIII are independent and distinct, each from the other, because they are products which possess characteristic differences in structure and function and each has an independent utility, that is distinct for each invention which cannot be exchanged.

Inventions V-VII are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case, the methods of diagnosis by detecting mutated nucleic acid molecules of Invention V have different modes of operation than the methods of diagnosis by detecting mutated proteins of Invention VI since the two methods have use different products (nucleic acid molecules vs proteins) to reach their conclusion and thus have different starting points, method steps and endpoints. Both methods of diagnosis of Inventions V and VI have different starting points, method steps, endpoints, and reach different goals than the method of treatment of Invention VII.

Invention I is related to Inventions V and VII as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the nucleic acid can be used in a method of making the protein, which is a materially different process than the methods of diagnosis and treatment of Inventions V and VII, respectively.

Art Unit: 1653

Inventions I and VI are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the nucleic acid molecules of Invention I are not made be nor used in the method of diagnosis by detecting mutated proteins of Invention VI.

Inventions II and V are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the probes could be used in a method of amplifying the full length PKD2 nucleic acid molecule by PCR or a method of finding PKD2 polymorphisms, which are materially different methods than the method of diagnosis of Invention V.

Invention II is unrelated to Inventions VI and VII. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case, the nucleic acid probe is not used in nor made by the processes of diagnosis or treatment of Inventions VI and VII.

Invention III is related to Inventions VI-VII as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different

Art Unit: 1653

process of using that product (MPEP § 806.05(h)). In the instant case, the protein could be used to make an antibody, which is a materially different method than the processes of diagnosis and treatment of Inventions VI and VII, respectively.

Inventions III and V are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the proteins of Invention III are not used in nor made by the method of diagnosis of Invention V.

Inventions IV and VI are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the antibody of Invention IV can be used in a method of purifying the protein, which is a materially different method than the method of diagnosis of Invention VI.

Invention IV is unrelated to Inventions V and VII. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the antibody of Invention IV is not used in nor made by the methods of diagnosis and treatment of Inventions V and VII.

Invention VIII is unrelated to Inventions V-VII. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different

Art Unit: 1653

modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the transgenic animal of Invention VIII is not used in nor made by the methods of diagnosis and treatment of Inventions V-VII.

Having shown that these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification and recognized divergent subject matter as defined by MPEP § 808.02, the Examiner has shown a serious burden of search (see MPEP § 803). Therefore, the initial requirement of restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Art Unit: 1653

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Holly Schnizer whose telephone number is (703) 305-3722. The examiner can normally be reached on Monday through Wednesday from 8 am to 5:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low can be reached on (703) 308-2923. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4242 for regular communications and (703) 308-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703 308-0196.

Holly Schnizer February 24, 2003

> KAREN COCHRANE CARLSON, PH.D PRIMARY EXAMINER

Kan (a ham (arker PM)